← All candidates
Two insider buys in the last year — $352.0K in all.
26 filings on record.
AGLagilon health, inc.
NYSE · Healthcare · $1.55B
$92.12
-0.28% · Sep 15
Two insider buys in the last year — $352.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 2 buys◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what AGL ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.55B
Float
10.9M
65% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
28.8
Price / sales
0.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Markets Officer
Shaker Benjamin
Bought $301.1K on Mar 2 — 500,000 sh @ $0.6021, held direct, 37% of their stake.
1 of 1 position beat the S&P
Director
Wulf John William
Bought $50.9K on Nov 12 — 81,000 sh @ $0.6289, held direct, 22% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
19 more transactions on Pro →Context
Wall St
$60.36 avg target
-34.5% vs today · 14 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26$2.32 act+$1.39
Q4 '25−$8.95 act−$2.10
Q3 '25−$6.40 act−$3.04
Q2 '25−$6.30 act−$3.64
Coverage
How Investors Are Reacting To agilon health (AGL) Scrutiny On Value-Based Medicare Advantage ExecutionSimply Wall St. · 07-063 Reasons AGL is Risky and 1 Stock to Buy InsteadStockStory · 06-29Agilon Health (AGL) Is Up 0.79% in One Week: What You Should KnowZacks · 06-26Why Fast-paced Mover Agilon (AGL) Is a Great Choice for Value InvestorsZacks · 06-26
The file stays open
26 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice